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Abstract
Introduction: Some studies have suggested that night work may be associated with an increased risk of breast
cancer in nurses. We aimed to explore the role of circadian gene polymorphisms in the susceptibility to night
work-related breast cancer risk.
Methods: We conducted a nested case-control study of Norwegian nurses comprising 563 breast cancer cases and
619 controls within a cohort of 49,402 Norwegian nurses ages 35 to 74 years. We studied 60 single-nucleotide
polymorphisms (SNPs) in 17 genes involved in the regulation of the circadian rhythm in cases and controls. The
data were analyzed in relation to the two exposure variables “maximum number of consecutive night shifts ever
worked” and “maximum number of consecutive night shifts worked for at least 5 years.” The odds of breast cancer
associated with each SNP was calculated in the main effects analysis and in relation to night shift work. The
statistically significant odds ratios were tested for noteworthiness using two Bayesian tests: false positive report
probability (FPRP) and Bayesian false discovery probability (BFDP).
Results: In the main effects analysis, CC carriers of rs4238989 and GG carriers of rs3760138 in the AANAT gene had
increased risk of breast cancer, whereas TT carriers of BMAL1 rs2278749 and TT carriers of CLOCK rs3749474 had
reduced risk. The associations were found to be noteworthy using both the FPRP and BFDP tests. With regard to
the effect of polymorphisms and night work, several significant associations were observed. After applying FPRP
and BFDP in women with at least four night shifts, an increased risk of breast cancer was associated with variant
alleles of SNPs in the genes AANAT (rs3760138, rs4238989), BMAL1 (rs2290035, rs2278749, rs969485) and ROR-b
(rs3750420). In women with three consecutive night shifts, a reduced risk of breast cancer was associated with
carriage of variant alleles of SNPs in CLOCK (rs3749474), BMAL1 (rs2278749), BMAL2 (rs2306074), CSNK1E (rs5757037),
NPAS2 (rs17024926), ROR-b (rs3903529, rs3750420), MTNR1A (rs131113549) and PER3 (rs1012477).
Conclusions: Significant and noteworthy associations between several polymorphisms in circadian genes, night
work and breast cancer risk were found among nurses who had worked at least three consecutive night shifts.
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Introduction
Breast cancer in women is the second leading cause of
mortality [1]. The etiology of breast cancer involves several
risk factors, such as early age at menarche, late age at
menopause, late age at first birth, nulliparity, hormonal
factors, ionizing radiation exposure and alcohol consump-
tion [2,3]. However, these known risk factors do not fully
explain the high incidence of breast cancer. Genetic fac-
tors are also involved in the etiology of breast cancer,
including rare high-risk mutations (BRCA1 and BRCA2),
more moderate susceptibility variants (CHEK2, ATM) and
several as yet unidentified common susceptibility variants
associated with low to moderate increased risk [4,5].
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At present, there is not sufficient evidence for any
occupational exposure to be classified as carcinogenic in
relation to breast cancer. However, night work is a
potential risk factor that has been found in many studies
to be associated with an elevated risk of breast cancer
[6-12]. A recent study reported that 4.6% of all female
breast cancers could be attributed to occupational expo-
sure to shift work [13]. This is important, given the
large proportion of women engaged in shift work and
the very high incidence of female breast cancer in gen-
eral. Although the majority of epidemiological studies
are suggestive of a positive association, not all studies
show a consistent association between night work and
increased risk of breast cancer [14-16].
Night work was classified as a Group 2A carcinogen by
the International Agency for Research on Cancer (IARC)
in 2007 [17,18]. The hypothesis of circadian disruption
by light at night (LAN) has received particular attention
in this evaluation [19]. Disruption of the circadian
rhythm has been hypothesized to increase cancer risk
through its impact on the production of the circadian
hormone melatonin [20,21]. A potential mechanism
could be through suppression of the nocturnal produc-
tion of melatonin, caused by exposure to LAN, which
may also influence the patterns of sex hormone produc-
tion and in turn influence breast cancer risk [22,23]. The
levels of melatonin are regulated through its biosynthesis
from the amino acid tryptophan, which is mediated by
the arylalkylamine N-acetyltransferase (AANAT) protein
or melatonin receptors MTNR1A (MT1) and MTNR1B
(MT2) and possibly the retinoic acid-related orphan
receptors ROR-a and ROR-b [24]. An antiproliferative
effect of melatonin has also been shown in human breast
cancer cell lines. In estrogen receptor-positive (ER+)
human breast cancer cells, melatonin suppresses both ER
mRNA expression and estrogen-induced transcriptional
activity of the ER [25,26]. Melatonin also regulates the
transcriptional activity of other enzymes involved in
estrogen metabolism and the expression of circadian and
circadian-targeted genes. Recently, melatonin was found
to induce apoptosis [27] and to reduce the levels of oxi-
dative stress [28,29]. Other mechanisms, such as impact
of sleep disruption on human physiological processes,
may also be involved [30], although not all the results of
studies on the impact of sleep disruption on breast can-
cer risk have been consistent [31,32].
The circadian clock is regulated by several proteins, such
as aryl hydrocarbon receptor nuclear translocator-likes
(ARNTL or BMAL1, ARNTL2 or BMAL2) also known as
Mop3, circadian locomotor output cycle kaput (CLOCK),
neuronal PAS domain protein 2 (NPAS2), periods (PER1,
PER2 and PER3), cryptochromes (CRY1 and CRY2),
TIMELESS, ROR-a and ROR-b, that interact with each
other in various transcriptional and translational feedback
loops [33]. The main signal is the daily light-dark rotation,
which is mediated by light-sensing opsin proteins such as
opsin 4 (OPN4) [34].
The circadian genes may affect cancer susceptibility
through effects on biological pathways that regulate
DNA damage and repair, carcinogen metabolism and/or
detoxification, cell growth and cell death [35]. It has
been shown that expression of the circadian gene PER1
may be downregulated in tumors and tumor cell lines
compared to normal cells [36]. The PER2 gene has been
shown to induce apoptosis through upregulation of the
tumor suppressor gene TP53 and the proapoptotic gene
Bax [37]. A PER2 gene mutation (S662G) also leads to
enhanced resistance to X-ray-induced apoptosis and
increased RAS-mediated oncogenic transformation, and
it affects tumorigenesis in mice [38].
To date, there are no genetic susceptibility biomarkers
identifying women who are particularly susceptible to
breast cancer related to exposure to night work. In parti-
cular, knowledge of how night work, together with com-
mon genetic variants in genes regulating the circadian
rhythm, may affect breast cancer risk is limited [39]. The
aim of this study was to analyze a number of polymorph-
isms in the core circadian genes and genes involved in
melatonin biosynthesis and melatonin bioavailability as
potential biomarkers of breast cancer risk in night
workers.
Methods
Case patients and controls
The details of study design, data collection, recruitment
of cases and controls have been described previously by
Lie et al. [8,9]. Briefly (see Additional File 1, Figure S1),
a nested case-control study of 1,182 women ages 35 to
74 years was performed within an established national
cohort of 49,402 Norwegian nurses who graduated
between 1914 and 1985. All of the women had been
diagnosed with histologically confirmed invasive breast
cancer between 1990 and 2007 (n = 1,132), were alive as
of February 2009 (n = 943), consented to be interviewed
(n = 706) and had an occupational history as a nurse of
at least 1 year (n = 699). The controls were frequency-
matched to cases by year of diagnosis and in 5-year age
groups. They were all cancer-free at and prior to the year
of diagnosis of the case, were alive as of February 2009
(n = 1,384), had consented to an interview (n = 900) and
worked as nurses for minimum of 1 year (n = 895).
Breast cancer cases were identified by linkage to the
Cancer Registry of Norway by personal identification
number given to all Norwegians alive since 1960. The
Cancer Registry of Norway has virtually complete records
of all cancer cases in the Norwegian population since
January 1953 [40]. Both cases and controls gave their full
informed consent that their information could be used
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and published for research purposes, given that their per-
sonal details would remain anonymous. The study was
approved by the Regional Committee for Medical and
Health Research Ethics, South-East region (S-08430a,
2008/10453).
Assessment of night work
Full details on the exposure assessment were described
in a recent study [9]. Briefly, different exposure metrics
of night work were computed on the basis of work his-
tory. The term night work in this study includes working
periods from rotating as well as permanent night sche-
dules. A “night shift” was defined as a shift including
work between 12 a.m. and 6 a.m. For each job, we
assessed information gathered for the year of start and
end, workplace (hospital, other institution and/or
others), proportion of full job and work schedule (only
day shifts, only night shifts or both day and night shifts).
If the job included night shifts, we also asked about the
number of night shifts per month, and number of con-
secutive night shifts. Two surrogate measures for night
work were applied: maximum number of consecutive
night shifts in all jobs (<3, 3 and ≥4) and maximum
number of consecutive night shifts the nurse had
worked during a minimum of 5 years (<3, 3 or ≥4).
We focused our analysis on the variable consecutive
night shift because, in our previous analysis [9], the con-
secutive night shift variable that takes duration into
account was the only variable found to be significantly
associated with an increased risk of breast cancer. In
that previous analysis, a positive trend was seen with an
increasing number of consecutive nights, albeit that a
significant association was observed only when compar-
ing those with at least 5 years of work in a job including
six or more consecutive night shifts with those who
never worked nights.
Collection of saliva and DNA extraction
DNA from 563 saliva samples taken from cases and 619
samples obtained from controls were isolated using the
Oragene·DNA isolation kit (DNA Genotek Inc, Kanata,
ON, Canada) as instructed by the manufacturer, with
some modifications. Briefly, 1 ml of saliva was trans-
ferred to an Eppendorf tube, and reagents provided by
the supplier were added. DNA was successfully
extracted from all saliva samples that were received.
Selection of polymorphisms and genotyping
The single-nucleotide polymorphism (SNP) selection strat-
egy was based primarily on a candidate gene approach
using information from a search of relevant studies pub-
lished by 2009. We searched the literature for polymorph-
isms in the core circadian genes and melatonin biosynthesis
and/or bioavailability that had been investigated for an
association with cancer risk. Since there were few poly-
morphisms that had been investigated by 2009, we also
included polymorphisms using one or more of the follow-
ing criteria: assumed functionality (located in the regulatory
regions, for example, 3’-UTR, 5’-UTR or amino acid
change), cancer genetic marker of susceptibility (CGEMS)
for breast cancer in epidemiological studies (candidate gene
or genome-wide association studies (GWASs)), candidate
tag SNP with r2 ≥ 0.80 and minor allele frequency (MAF) ≥
5%, and location in the relevant circadian, melatonin and
light signaling pathways. Because of the constraint of the
project budget, and hence limitations on the number of
polymorphisms that could be placed on the chip, 60 SNPs
were successfully designed and genotyped (see Additional
File 2, Tables S1 and S2). The genotyping success rate
was similar in cases and controls: at least 0.80 in cases and
0.82 in controls. All SNPs except for one SNP in the CRY2
gene (rs12364060) and one SNP in the MTNR1A gene
(rs2119882) were in Hardy-Weinberg equilibrium. Two
previously reported SNPs, rs35670208 in the ARNTL2/
BMAL2 gene and rs28936679 in the AANAT gene, respec-
tively, were found to be nonpolymorphic in this population.
Genotyping was performed using the iPLEX genotyping
assay (Sequenom Inc, San Diego, CA, USA) at the Centre
for Integrative Genetics (CIGENE) genotyping core facility
at the University for Environment and Biosciences, Ås,
Norway.
Statistical methods
Pearson’s c2 test was used to assess case-control differ-
ences in the frequency distribution of categorical variables,
and a nonparametric Mann-Whitney test was used to
assess differences in median age between cases and con-
trols. On the basis of existing knowledge of factors asso-
ciated with breast cancer, the following factors were
regarded as potential confounders: age at time of diagnosis
(as a continuous variable in 5-years age groups), period of
diagnosis (1996 to 1999 and 2000 to 2007), parity (0, 1 or
2 or ≥3 children), family history of breast cancer in mother
and/or sister (no or yes), use of hormone treatment during
the 2 years before the reference year (no or premenopau-
sal, or yes) and frequency of alcohol consumption at time
of diagnosis (less than twice weekly or at least twice per
week). These variables were included in the final logistic
regression model to obtain adjusted odds ratios (ORs) for
developing breast cancer associated with the frequency of
polymorphisms alone (main effects analysis), the poly-
morphisms and night work (stratified by number of conse-
cutive night shifts). On the basis of the results of our
previous study showing associations between intensity of
night work and breast cancer risk, we examined the simul-
taneous effects of polymorphisms and night work by com-
paring the frequency of genotypes of each polymorphism
in cases and controls who had worked either at least four
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and three consecutive night shifts with a reference group
who had worked only day shifts or a maximum of two
consecutive night shifts. We compared the frequency of
SNPs in subgroups defined by both intensity (number
of consecutive nights) and duration (number of years) of
night work. In our previous study [9], the consecutive
night shift variable that takes duration into account was
the only variable found to be significantly associated with
an increased risk of breast cancer, that is, a significant
association was observed only when individuals with at
least 5 years of work experience in a job including six or
more consecutive night shifts were compared with those
who had never worked nights. A positive trend was seen
with increasing number of consecutive nights, however,
thus, to avoid small numbers of subjects in the stratified
analyses in the present study, women who had worked at
least four consecutive night shifts were classified as the
most exposed group. The relative risk of breast cancer
associated with each genotype was estimated as OR with
95% confidence interval (CI) using unconditional logistic
regression models. For determination of interactions
between the shift work and SNP genotypes, the product of
shift work × genotype variables was added to the model.
Interaction P values (P interaction) are reported for the
joint effects of shift work and genotype. All reported
P values are two-sided. P < 0.05 was considered statisti-
cally significant. All statistical analyses were carried out
using SPSS release 21 software (SPSSInc, Chicago, IL,
USA).
Multiple testing and false discovery rates
To evaluate the possibility of false-positives due to mul-
tiple testing, we applied two Bayesian statistical tests,
false positive report probability (FPRP) and the Bayesian
false discovery probability (BFDP), that have been used
frequently to test noteworthiness of findings in genetic
association studies [41-43]. The FPRP statistical tool was
introduced by Wacholder et al. [42] as a means to
assess whether the strength of an association is note-
worthy in the case of multiple hypothesis testing. In
addition, we used the BFDP, which is a recent further
development of FPRP [41]. We performed both FPRP
and BFDP tests for each SNP. For both tests, we chose
the noteworthiness thresholds (FPRP 0.2 and BFDP 0.8)
following the original papers [41,42]. We considered
noteworthy only those associations that passed both
tests. We have set low prior probability values compared
to what commonly has been used [44].
Results
The study design is a nested case-control study (see
Additional File 1, Figure S1). The original cohort study
of Norwegian nurses was described in detail by Lie et al.
[8,9]. The demographic characteristics of cases and
controls (Table 1) are not significantly different, except
for the presence of breast cancer in mother or sister.
The exposure parameters and the number of cases and
controls in each exposure group are shown in Table 2.
The selected circadian genes, chromosome locations and
the protein function of each respective gene are shown
in Additional File 2, Table S1. The SNPs with corre-
sponding reference SNP (rs) numbers, SNP types, base
changes, MAF, Hardy-Weinberg-derived P values and
genotyping rates are given in Additional File 2, Table S2.
Sixty SNPs in 17 genes (see Additional File 2, Tables
S1 and Table S2) from the circadian signaling pathway
were analyzed for association with breast cancer risk. As
shown in Additional File 2, Table S2, the MAFs of the
SNPs in controls were similar to those reported pre-
viously in Caucasian populations, indicating the validity
of the genotyping methodology [45-47].
The analysis of main effects, without regard to night
work (significant associations are shown in Table 3),
showed that four SNPs were associated with breast can-
cer risk: CC carriers of the AANAT rs4238989 with an
OR of 1.43 (95% CI, 1.01- 2.01) and GG carriers of
AANAT rs3760138 with an OR of 1.42 (95% CI, 1.01-
2.01) had increased risk of breast cancer. The carriers of
variant TT genotype of SNP rs2278749 in the BMAL1
gene with an OR of 0.45 (95% CI, 0.23- 0.90) and the
homozygote genotype TT of rs3749474 in the CLOCK
gene with an OR of 0.64 (95% CI, 0.45- 0.92) had
reduced risk of breast cancer. All of these associations
were found to be noteworthy for both FPRP (<0.2) and
BFDP (<0.8).
Compared to the reference group (Table 4), in the high-
est exposed group with at least four consecutive night
shifts, CLOCK rs11133373 (OR 2.75, 95% CI 1.07- 7.09),
ROR-b rs3903529 (OR 1.87, 95% CI 1.0- 3.61), two SNPs
in the AANAT gene (rs3760138 (OR 1.82, 95% CI 1.13-
2.93) and rs4238989 (OR 1.62, 95% CI 1.0- 2.68)) and
MTNR1B-rs10830963 (OR 2.48, 95% CI 1.06- 5.8) were
associated with increased risk of breast cancer. In the
same group, two SNPs in the CRY2 gene, rs11038689 (OR
0.42, 95% CI 0.17- 1.01) and rs1401417 (OR 0.31, 95% CI
0.10- 0.94), were associated with reduced risk. In the
group with three night shifts, a reduced risk of breast can-
cer was associated with the presence of one variant allele
(heterozygote) or two variant alleles (homozygote) for
SNPs in CLOCK rs11133373 (OR 0.50, 95% CI 0.25- 0.99),
CLOCK rs3749474 (OR 0.56, 95% CI 0.31- 0.99); ROR-b
rs3903529 (OR 0.57, 95% CI 0.34- 0.95), ROR-b rs7022435
(OR 0.16, 95% CI 0.05- 0.55); ROR-b rs7022435 (OR 0.17,
95% CI 0.03- 0.84); ROR-b rs3750420 (OR 0.40, 95% CI
0.18- 0.88) and MTNR1A rs 13113549 (OR 0.50, 95% CI
0.28- 0.90).
The cases and controls were then grouped according
to both intensity and duration of night work, that is,
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maximum number of consecutive nights they had ever
worked for at least 5 yr. In subjects with at least four
consecutive night shifts, increased risk of breast cancer
was associated with variant alleles of BMAL1 (rs2290035
(OR 1.91, 95% CI 1.08- 3.37; and OR 1.95, 95% CI 0.97-
3.90) and rs969485 (OR 1.64, 95% CI 1.03- 2.61; and
OR 1.63, 95% CI 0.96- 2.76)) and ROR-b (rs3750420
(OR 1.60, 95% CI 1.0- 2.56), rs3903529 (OR 2.77, 95%
CI 0.98- 7.86)) and MTNR1B rs10830963 (OR 9.12, 95%
CI 1.14- 73.09). In the group with three consecutive
night shifts, the SNP rs11695472 in the PER2 gene (OR
2.69, 95% CI 1.08- 6.73) was associated with increased
risk of breast cancer. The SNPs BMAL1 rs2278749 (OR
0.51, 95% CI 0.29- 0.87), BMAL2 rs2306074 (OR 0.30,
95% CI 0.17- 0.75), CLOCK rs3749474 (OR 0.24, 95% CI
0.05 to 1.18), CSNK1E (rs1534891 (OR 0.55, 95% CI
0.30- 1.01), rs5757037 (OR 0.67, 95% CI 0.45- 0.99)),
NPAS2 rs17024926 (OR 0.33, 95% CI 0.13- 0.84; and
OR 0.24, 95% CI 0.09- 0.67); PER3 rs1012477 (OR 0.42,
0.24- 0.72; and OR 0.38, 95% CI 0.18- 0.66), ROR-b
(rs7022435 (OR 0.25, 95% CI 0.07- 0.89), rs3750420 (OR
0.37, 95% CI 0.14- 0.96; and OR 0.33, 95% CI 0.11- 1.0))
and MTNR1A rs131113549 (OR 0.47, 95% CI 0.25-
0.91) were associated with decreased breast cancer risk
(Table 5).
After applying FPRP and BFDP tests, in subjects with
four or more night shifts (Table 4), increased risk of breast
cancer associated with homozygote carriers of the variant
alleles of SNPs rs3760138 and rs4238989 in the AANAT
gene was found to be noteworthy. In subjects with three
consecutive night shifts, the odds of reduced risk of breast
cancer associated with carriage of variant alleles of SNPs
in CLOCK (rs3749474), ROR-b (rs3903529, rs3750420)
and MTNR1A (rs131113549) were found noteworthy.
Table 1 Characteristics of controls and breast cancer cases.
Parameter Cases (n = 563) Controls (n = 619) P value
Age (yr)a 0.51b




1996 to 1999/2000 to 2007 (n) 195/368 221/398 0.72c
Breast cancer in first-degree familyd (n) 557 615
Yes/no 104/453 54/561 <0.001c
Hormone therapy in past 2 yre (n) 552 605
Yes/no 127/425 121/484 0.22c
Alcohol usef n = 563 n = 619
Yes/no 43/520 37/582 0.26c
Children (n) 563 619
0/≥1 77/486 81/538 0.80c
aAge at selection for controls and age at diagnosis for cases. bDerived from Mann-Whitney U-test for two independent samples (two-sided) assuming the
medians are the same across cases and controls. cPearson’s c2 test (two-sided). d Cancer in sister or mother. eHormone therapy among postmenopausal women
only. fAlcohol consumption at least twice weekly.
Table 2 Occupational exposure data and number of cases and controls in each exposure group.




Only day work or one or two consecutive night shifts (reference) 170 (227) 186 (275)
Three consecutive night shifts 156 (181) 189 (272)
Four or more consecutive night shifts 239 (291) 244 (348)
Total 563 (699) 619 (895)
Intensity of night work: Maximum number of consecutive night shifts the nurse has ever worked for 5 or
more yearsc
Only day work or one or two consecutive nights for 5 or more years (reference) 326 (421) 362 (524)
Three consecutive night shifts for 5 or more years 125 (147) 154 (227)
Four or more consecutive night shifts for 5 or more years 112 (131) 103 (144)
Total 563 (699) 619 (895)
aMaximum number of consecutive night shifts in all jobs: 0 to 2, 3 or ≥4. bNumber of nurses who had consented to send saliva for genetic analysis (numbers in
parentheses show the total number of cases and controls interviewed in each exposure group). cMaximum number of consecutive night shifts the nurse has ever
worked for 5 or more years.
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With respect to both intensity and duration of night shift
work for at least 5 yr (Table 5), in subjects with at least
four consecutive night shifts, increased risk of breast cancer
was associated with variant alleles of BMAL1 (rs2290035,
rs969485) and ROR-b (rs3750420). In the subjects with
three night shifts, SNPs in BMAL1 (rs2278749), BMAL2
(rs2306074), CSNK1E (rs5757037), NPAS2 (rs17024926),
PER3 (rs1012477) and MTNR1A (rs131113549) were asso-
ciated with decreased breast cancer risk. Haplotype analysis
of the polymorphisms localized on the same chromosome
did not result in any significant associations (data not
shown).
Discussion
In the main effects analysis, two SNPs in BMAL1 and
CLOCK were associated with risk of breast cancer. There
are no functional data to explain how each SNP in each of
the genes may affect the risk for breast cancer. SNPs may
change transcription binding affinity of the BMAL1/
CLOCK complex that is necessary for expression of the
target genes. For example, a reduced affinity of BMAL1/
CLOCK to CLOCK promoter due to polymorphisms in
these genes may lead to lower expression of CLOCK pro-
teins. A reduction in the levels of another core circadian
protein (CRY2) in breast epithelial cells in culture has
been shown to lead to higher accumulation of DNA
damage after exposure to chemical mutagens [48,49].
Downregulation of CLOCK has also been reported to
cause alterations in expression of genes involved in breast
carcinogenesis [50].
Several SNPs in the core circadian genes had noteworthy
associations with breast cancer risk. Women with the
highest number of successive night shifts and carrying at
least one variant allele of SNPs in the two core circadian
genes BMAL1 (rs2290035, rs969485) and ROR-b
(rs3903529, rs3750420) had a noteworthy increased risk of
breast cancer. Although not noteworthy, there was also a
2.75 increased risk of breast cancer in women who had
worked four or more night shifts and carrying two variant
G alleles of CLOCK rs111133373 compared to women
with the same genotype in the reference group. Interest-
ingly, women with three successive night shifts and
Table 3 Odds ratios and 95% confidence intervals for polymorphisms with statistically significant associations with
risk of breast cancer.
Genes and SNPs Frequency of genotypesa OR (95% CI)b Pc FPRPd BFDPe
BMAL1 No. of cases No. of controls
rs2278749
CC 375 381 1.0
CT 141 164 0.93 (0.70- 1.22)




CC 223 228 1.0
CT 251 260 1.01 (0.78- 1.31)




TT 149 181 1.0
TG 269 315 1.00 (0.75- 1.32)
GG 128 106 1.42 (1.01- 2.01) 0.05 0.13 0.18
Ptrend = 0.07
rs4238989
GG 161 203 1.0
GC 263 288 1.13 (0.86- 1.49)
CC 120 104 1.43 (1.01- 2.01) 0.04 0.11 0.16
Ptrend = 0.13
aNumber of cases and controls with successful genotyping data. bOdds ratios (ORs) derived from unconditional logistic regression and adjusted for age at
diagnosis (cases) or day of reference (controls), selection period, alcohol use, hormone replacement therapy for the past 2 years, number of children and history
of breast cancer in first-degree family (mother or sister). cPearson’s c2 test (two-sided) comparing frequency of the homozygote variant genotypes with
homozygote common genotypes (reference). dThe false-positive report probability (FPRP) was calculated as described by Wacholder et al. [42]. FPRP < 0.2 was
considered noteworthy. eThe Bayesian false-discovery probability (BFDP) was calculated as described by Wakefield et al. [41]. BFDP < 0.8 was considered
noteworthy. For more details on FPRP and BFDP, see Methods section. Ptrend values for the Cochran-Armitage trend test were calculated from 2×C tables using
frequency of cases and controls.
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Table 4 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each
polymorphism among women with less than two consecutive night shifts compared to women with three consecutive
night shifts or women with four or more consecutive night shifts.
Genes and SNPs Number of consecutive night shifts that nurse has worked in all jobs
0 to 2 consecutive night
shifts
Three consecutive night shifts ≥4 consecutive night shifts
Caa/Coa OR (95% CI)b Caa/Coa OR (95% CI)b Pinter




CC 72/77 1.0 (reference) 71/68 0.82 (0.52 - 1.30) 103/99 1.29 (0.79 - 2.11)
CG 76/72 0.98 (0.61 -1.57) 58/82 0.77 (0.53 - 1.13) 93/114 0.87 (0.63 - 1.20)
GG 14/25 1.05 (0.49 - 2.29) 13/29 0.50 (0.25 - 0.99) 0.05 0.22 0.23 28/23 1.17 (0.65 - 2.10)
Ptrend
f = 0.04 Ptrend
f = 0.95
CC 72/77 1.0 (reference) 71/68 0.82 (0.52 - 1.30) 103/99 1.29 (0.79 - 2.11)
CG 76/72 1.0 (reference) 58/82 0.88 (0.56 - 1.39) 93/114 0.79 (0.48 - 1.30)
GG 14/25 1.0 (reference) 13/29 0.83 (0.34 - 2.04) 28/23 2.75 (1.07 - 7.09) 0.04 0.30 0.25
rs3749474
CC 67/71 1.0 (reference) 60/66 0.95 (0.57 - 1.57) 96/91 1.14 (0.72 - 1.80)
CT 77/76 1.12 (0.69-1.81) 73/78 1.01 (0.70 - 1.46) 101/106 1.03 (0.74 - 1.42)
TT 16/30 0.55 (0.27-1.14) 20/37 0.56 (0.31 - 0.99) 0.05 0.18 0.21 32/41 0.85 (0.52 - 1.39)
Ptrend
f = 0.30 Ptrend
f = 0.54
CC 67/71 1.0 (reference) 60/66 0.95 (0.57 - 1.57) 96/91 1.14 (0.72 - 1.80)
CT 77/76 1.0 (reference) 73/78 0.93 (0.58 - 1.48) 101/106 0.98 (0.63 - 1.51)
TT 16/30 1.0 (reference) 20/37 1.10 (0.46 - 2.61) 32/41 1.35 (0.61 - 3.00)
CRY2
rs11038689
AA 87/97 1.0 (reference) 84/97 0.99 (0.67 - 1.47) 127/127 1.36 (0.87 - 2.13)
AG 52/55 1.10 (0.66 - 1.81) 45/57 0.82 (0.54 - 1.26) 68/70 0.94 (0.65 - 1.37)
GG 8/11 0.86 (0.32 - 2.28) 13/12 1.11 (0.49 - 2.51) 7/20 0.42 (0.17 - 1.01) 0.05 0.31 0.25
Ptrend
f = 0.91 Ptrend
f = 0.39
AA 87/97 1.0 (reference) 84/97 0.99 (0.67 - 1.47) 127/127 1.36 (0.87 - 2.13)
AG 52/55 1.0 (reference) 45/57 0.98 (0.58 - 1.68) 68/70 0.82 (0.46 - 1.47)
GG 8/11 1.0 (reference) 13/12 0.44 (0.09 - 2.06) 7/20 1.44 (0.33 - 6.20)
rs1401417
CC 78/94 1.0 (reference) 75/95 1.01 (0.65 - 1.58) 119/120 1.27 (0.84 - 1.91)
CG 46/54 1.10 (0.65-1.86) 40/56 0.76 (0.49 - 1.18) 72/68 1.13 (0.77 - 1.64)
GG 8/8 1.36 (0.47-3.94) 10/13 0.86 (0.37 - 2.01) 4/17 0.31 (0.10 - 0.94) 0.04 0.37 0.26
Ptrend
f = 0.61 Ptrend
f = 0.78
CC 78/94 1.0 (reference) 75/95 1.01 (0.65 - 1.58) 119/120 1.27 (0.84 - 1.91)
CG 46/54 1.0 (reference) 40/56 0.76 (0.42 - 1.37) 72/68 1.11 (0.65 - 1.90)
GG 8/8 1.0 (reference) 10/13 0.22 (0.18 to 3.74) 4/17 0.25 (0.05 to 1.37)
NPAS2
rs2305160
GG 75/72 1.0 (reference) 58/71 0.78 (0.48 - 1.28) 105/90 1.16 (0.74 - 1.81)
GA 61/74 0.82 (0.50 - 1.33) 69/83 0.87 (0.60 - 1.25) 94/104 0.93 (0.67 - 1.29)
AA 25/27 0.89 (0.46 - 1.72) 21/28 0.73 (0.40 - 1.34) 27/35 0.87 (0.51 - 1.50)
Ptrend
f = 0.26 Ptrend
f = 0.21
GG 75/72 1.0 (reference) 58/71 0.78 (0.48 - 1.28) 105/90 1.16 (0.74 - 1.81)
GA 61/74 1.0 (reference) 69/83 1.06 (0.65 - 1.73) 94/104 1.12 (0.71 - 1.76)
AA 25/27 1.0 (reference) 21/28 0.76 (0.33 - 1.72) 27/35 0.86 (0.39 - 1.92)
ROR-b
rs3903529
TT 76/100 1.0 (reference) 81/89 1.29 (0.82 - 2.01) 120/111 1.41 (0.93 - 2.14)
TA 72/58 1.67 (1.03 - 2.70) 51/73 0.74 (0.49 - 1.10) 81/109 0.81 (0.58 - 1.13)
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Table 4 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each polymorph-
ism among women with less than two consecutive night shifts compared to women with three consecutive night
shifts or women with four or more consecutive night shifts. (Continued)
AA 10/16 0.89 (0.37 - 2.15) 12/19 0.61 (0.29 - 1.31) 27/15 1.87 (1.00 - 3.61) 0.06 0.24 0.24
Ptrend
f = 0.60 Ptrend
f = 0.28
TT 76/100 1.0 (reference) 81/89 1.29 (0.82 - 2.01) 120/111 1.41 (0.93 - 2.14)
TA 72/58 1.0 (reference) 51/73 0.57 (0.34 - 0.95) 0.03 0.12 0.18 81/109 0.66 (0.41 - 1.05)
AA 10/16 1.0 (reference) 12/19 0.91 (0.30 - 2.80) 27/15 2.47 (0.83 - 7.34)
Ptrend = 0.03
rs7022435
GG 89/100 1.0 (reference) 92/101 1.06 (0.69 - 1.62) 124/134 1.06 (0.71 - 1.57)
GA 65/62 1.21 (0.75 -1.93) 53/63 0.93 (0.61 - 1.40) 82/84 1.05 (0.75 - 1.49)
AA 8/9 1.12 (0.41 - 3.06) 3/18 0.16 (0.05 - 0.55) 0.004 0.24 0.23 18/12 1.55 (0.73 - 3.30)
Ptrend
f = 0.21 Ptrend
f = 0.31
rs7022435
GG 89/100 1.0 (reference) 92/101 1.06 (0.69 - 1.62) 124/134 1.06 (0.71 - 1.57)
GA 65/62 1.0 (reference) 53/63 0.81 (0.48 - 1.37) 82/84 0.93 (0.58 - 1.49)
AA 8/9 1.0 (reference) 3/18 0.17 (0.03 - 0.84) 0.03 0.49 0.28 18/12 1.68 (0.44 - 6.33)
rs3750420
CC 68/87 1.0 (reference) 68/80 1.12 (0.70 - 1.81) 93/112 1.03 (0.66 - 1.61)
CT 76/72 1.35 (0.84 - 2.18) 68/72 1.11 (0.76 - 1.62) 100/92 1.32 (0.95 - 1.83)
TT 13/15 1.25 (0.54 - 2.87) 9/25 0.40 (0.18 - 0.88) 0.02 0.19 0.22 29/21 1.57 (0.87 - 2.83)
Ptrend
f = 0.58 Ptrend
f = 0.04
CC 68/87 1.0 (reference) 68/80 1.12 (0.70 - 1.81) 93/112 1-03 (0.66 - 1.61)
CT 76/72 1.0 (reference) 68/72 0.91 (0.56 - 1.48) 100/92 1.13 (0.72 - 1.76)
TT 13/15 1.0 (reference) 9/25 0.34 (0.11 - 1.05) 29/21 1.35 (0.51 - 3.58)
AANAT
rs3760138
TT 38/52 1.0 (reference) 42/57 0.93 (0.51 - 1.70) 69/72 1.19 (0.68 - 2.08)
TG 86/85 1.17 (0.68 - 2.00) 75/95 0.87 (0.61 - 1.24) 108/135 0.91 (0.67 - 1.24)
GG 40/42 1.18 (0.63 - 2.21) 33/32 1.23 (0.72 - 2.08) 55/32 1.82 (1.13 - 2.93) 0.01 0.06 0.14
Ptrend
f = 0.03 Ptrend
f = 0.04
TT 38/52 1.0 (reference) 42/57 0.93 (0.51 - 1.70) 69/72 1.19 (0.68 - 2.08)
TG 86/85 1.0 (reference) 75/95 0.80 (0.51 - 1.25) 108/135 0.82 (0.54 - 1.23)
GG 40/42 1.0 (reference) 33/32 1.28 (0.64 - 2.57) 55/32 1.84 (0.94 - 3.62)
rs4238989
GG 43/60 1.0 (reference) 50/59 1.13 (0.64 - 2.01) 68/84 1.07 (0.62 - 1.83)
GC 77/82 1.20 (0.72 - 2.02) 66/86 0.87 (0.60 - 1.27) 120/120 1.18 (0.87 - 1.61)
CC 40/35 1.47 (0.79 - 2.74) 37/39 1.15 (0.70 - 1.88) 43/30 1.62 (1.00 - 2.68) 0.06 0.19 0.22
Ptrend
f = 0.49 Ptrend
f = 0.02
GG 43/60 1.0 (reference) 50/59 1.13 (0.64 - 2.01) 68/84 1.07 (0.62 - 1.83)
GC 77/82 1.0 (reference) 66/86 0.85 (0.53 - 1.37) 120/120 1.11 (0.73 - 1.68)
CC 40/35 1.0 (reference) 37/39 1.02 (0.52 - 2.01) 43/30 1.40 (0.69 - 2.83)
MTNR1A
rs13113549
TT 51/60 1.0 (reference) 64/58 1.36 (0.79 - 2.34) 81/78 1.37 (0.82 - 2.27)
TC 84/88 1.19 (0.72-1.96) 67/80 0.89 (0.61 - 1.30) 102/96 1.08 (0.78 - 1.50)
CC 26/29 1.12 (0.57-2.20) 20/42 0.50 (0.28 - 0.90) 0.02 0.11 0.18 47/56 0.82 (0.54 - 1.26)
Ptrend
f = 0.11 Ptrend
f = 0.95
TT 51/60 1.0 (reference) 64/58 1.36 (0.79 - 2.34) 81/78 1.37 (0.82 - 2.27)
TC 84/88 1.0 (reference) 67/80 0.88 (0.55 - 1.40) 102/96 1.11 (0.73 - 1.71)
CC 26/29 1.0 (reference) 20/42 0.55 (0.25 - 1.23) 47/56 0.79 (0.40 - 1.59)
MTNR1B
rs10830963
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carrying the same SNPs and genotypes had a reduced risk
of breast cancer, indicating a protective role for these
genetic variants. In addition, women in this exposure
group carrying at least one variant allele of several SNPs in
the other core circadian genes such as BMAL2, CSNK1E,
NPAS2 and PER3 had a noteworthy reduced risk of breast
cancer. For comparison, only two SNPs in the CRY2 gene
(rs11038689 and rs1401417) had protective effects in
women with four or more night shifts, though this effect
was not noteworthy.
Many of the associations, such as PER3 (rs1012477),
CSNK1E (rs1534891) and CLOCK (rs11133373, rs3749474),
are novel in relation to breast risk but may not be specific
to breast cancer, because they have also been found to be
associated with prostate and colorectal cancer risk [47,51].
It might be that these SNPs affect expression of the respec-
tive genes. Current results from the available literature
on the functionality of other SNPs in these genes are not
conclusive. For example, it has previously been seen that, in
healthy nurses and midwives who worked either day or
rotating night shifts, there were no differences between
BMAL1, CLOCK, CRY1, CRY2, PER1, PER2 and PER3 gene
expression levels in peripheral blood leukocytes [52]. In the
same subjects, however, polymorphisms of the circadian
genes BMAL1 (rs2279287), CLOCK (rs1801260), PER1
(rs2735611), PER2 (rs2304672), PER3 (rs10462020), CRY1
(rs8192440) and CRY2 (rs10838527, rs10838527) were not
found to be different between shift workers and day-only
workers [53].
In a recent study by Monsees et al. [54], the SNP
rs2305160 (Ala394Thr) in the NPAS2 gene was found to
be associated with reduced breast cancer risk in women
with less than 2 yr of shift work. We were not able to con-
firm such an association in our study; however, for
another SNP, rs17024926 in the NPAS2 gene, we found a
reduced risk of breast cancer in shift workers who had
worked three night shifts for at least 5 yr (Table 5). The
reduced risk was associated with the variant homozygote
genotype where carriers of the CC variant genotype had
reduced risk of breast cancer compared to subjects who
had worked no or few night shifts carrying either the var-
iant CC genotypes or the common TT genotype (Table 5).
The NPAS2 rs17024926 has been found to be associated
with risk of prostate cancer [47]. This SNP was not geno-
typed in the study by Monsees et al. [54]; however, the
reasons why the results of our study and those of Monsees
et al. differ for Ala394Thr variant are not known. This dif-
ference could not be due to differences in MAF in the two
populations, first because the MAF 0.37 for this SNP in
our population (Additional File 2, Table S2) is similar to
the MAF 0.34 in the study by Monsees et al., and second
because we regenotyped this SNP in our subjects and
again found no associations. There could be several other
possibilities, such as differences in study design, popula-
tion differences in incidence of breast cancer, exposure
metrics and the fact that breast cancer is known to be a
genetically heterogeneous disease. Nevertheless, both stu-
dies support a role of circadian genes in breast cancer in
shift workers, which warrants further confirmation and
validation in future studies.
Increased risk of breast cancer in women with four or
more night shifts was associated with ROR-b SNPs
rs3903529 and rs3750420 (heterozygotes), whereas women
with three night shifts and carrying a homozygote variant
of rs7022435 and rs3750420 had reduced risk. The three
SNPs are located in intron 1 downstream of the exon 1 in
the ROR-b transcripts. These SNPs are part of a haplotype
block that spans the region containing the promoter
region and the exon 1 (55 kb upstream to 6 kb down-
stream) of the gene. This haplotype has also been asso-
ciated with an increased risk of human bipolar syndrome
[55], but we were not able to find such an association with
Table 4 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each polymorph-
ism among women with less than two consecutive night shifts compared to women with three consecutive night
shifts or women with four or more consecutive night shifts. (Continued)
CC 95/97 1.0 (reference) 76/103 0.74 (0.48 - 1.13) 119/129 0.90 (0.61 - 1.34)
CG 56/69 0.74 (0.46 - 1.19) 55/60 1.04 (0.69 - 1.56) 86/90 1.06 (0.76 - 1.49)
GG 7/8 0.76 (0.25 - 2.32) 15/13 1.29 (0.59 - 2.81) 19/8 2.48 (1.06 - 5.80) 0.04 0.26 0.24
Ptrend
f = 0.99 Ptrend
f = 0.35
CC 95/97 1.0 (reference) 76/103 0.74 (0.48 - 1.13) 119/129 0.90 (0.61 - 1.34)
CG 56/69 1.0 (reference) 55/60 1.18 (0.70 - 2.00) 86/90 1.23 (0.76 - 1.97)
GG 7/8 1.0 (reference) 15/13 1.55 (0.38 - 6.37) 19/8 3.51 (0.73 - 16.96)
aNumber of cases and controls that were successfully genotyped. bOR derived from unconditional logistic regression, including an interaction term between the
night shift variable and the SNP genotypes and adjusted for age at diagnosis (cases) or interview (controls), selection period, alcohol use, hormone replacement
therapy for the past 2 years, number of children and history of breast cancer in first-degree family members (mother or sister). cP interaction was obtained from
the interaction term between the SNP genotypes and the night shift variable using frequency of the common genotype in the 0 to 2 night shift group as
reference. Only significant or near-significant values are shown. dThe false-positive report probability (FPRP) was calculated as described by Wacholder et al. [42].
FPRP < 0.2 was considered noteworthy. eThe Bayesian false discovery probability (BFDP) was calculated as described by Wakefield et al. [41]. BFDP < 0.8 was
considered noteworthy. For more details on FPRP and BFDP, see the Methods section. fPtrend values for Cochran-Armitage trend test were calculated from 2×C
tables using frequency of genotypes in cases and controls from 0 to 2 night shift group as reference.
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Table 5 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each
polymorphism among women with less than two consecutive night shifts for 5 or more years compared to women
with three consecutive night shifts or women with four or more consecutive night shifts for 5 or more years
Genes and
SNPs
Number of consecutive night shifts nurse has ever worked for 5 or more years
0 to 2 consecutive
nights
3 consecutive nights 4 or more consecutive nights
Caa/
Coa
OR (95% CI)b Caa/
Coa











TT 106/121 1.0 (reference) 40/46 0.98 (0.58 - 1.65) 26/26 0.99 (0.53 - 1.88)
TA 149/161 1.03 (0.72 -
1.47)
66/71 1.04 (0.71 - 1.51) 46/50 1.02 (0.66 - 1.57)
AA 50/61 0.95 (0.59 -
1.52)
16/27 0.69 (0.36 - 1.34) 36/21 1.91 (1.08 - 3.37) 0.03 0.12 0.19
Ptrend
f = 0.60 Ptrend
f = 0.08
TT 106/121 1.0 (reference) 40/46 0.98 (0.58 - 1.65) 26/26 0.99 (0.53 - 1.88)
TA 149/161 1.0 (reference) 66/71 0.99 (0.65 - 1.50) 46/50 1.10 (0.64 - 1.63)
AA 50/61 1.0 (reference) 16/27 0.75 (0.35 - 1.60) 36/21 1.95 (0.97 - 3.90) 0.06 0.25 0.24
rs2278749
CC 212/231 1.0 (reference) 97/92 1.19 (0.84 - 1.70) 66/58 1.26 (0.83 - 1.91)
CT 86/87 1.19 (0.83 -
1.73)
22/45 0.51 (0.29 - 0.87) 0.01 0.07 0.15 33/32 1.10 (0.64 - 1.84)
TT 7/19 0.40 (0.16 -
0.98)
1/5 0.26 (0.03 - 2.38) 5/6 0.84 (0.25 - 2.82)
Ptrend
f = 0.07 Ptrend
f = 0.52
CC 212/231 1.0 (reference) 97/92 1.19 (0.84 - 1.70) 66/58 1.26 (0.83 - 1.91)
CT 86/87 1.0 (reference) 22/45 0.47 (0.25 - 0.88) 0.02 0.12 0.18 33/32 0.99 (0.55 - 1.79)
TT 7/19 1.0 (reference) 1/5 1.33 (0.10 - 17.78) 5/6 2.68 (0.48 - 15.01)
rs969485
AA 161/189 1.0 (reference) 51/74 0.83 (0.54 - 1.28) 41/50 0.92 (0.57 - 1.49)
AG 105/117 1.05 (0.74 -
1.49)
58/55 1.23 (0.82 - 1.85) 50/35 1.64 (1.03 - 2.61) 0.04 0.12 0.18
GG 21/20 1.07 (0.54 -
2.09)
8/8 1.40 (0.50 - 3.94) 9/7 1.50 (0.53 - 4.22)
Ptrend
f = 0.49 Ptrend
f = 0.05
AA 161/189 1.0 (reference) 51/74 0.83 (0.54 - 1.28) 41/50 0.92 (0.57 to 1.49)
AG 105/117 1.0 (reference) 58/55 1.50 (0.72 - 1.85) 50/35 1.63 (0.96 - 2.76) 0.07 0.21 0.23




TT 143/144 1.0 (reference) 58/63 0.91 (0.59 - 1.43) 51/53 0.97 (0.61 - 1.53)
TC 134/163 0.84 (0.60 -
1.17)
60/68 0.97 (0.66 - 1.42) 50/40 1.36 (0.86 - 2.13)
CC 37/39 1.04 (0.61 -
1.76)
6/21 0.30 (0.17 - 0.75) 0.01 0.18 0.21 9/9 1.03 (0.39 - 2.72)
Ptrend
f = 0.06 Ptrend
f = 0.51
TT 143/144 1.0 (reference) 58/63 0.91 (0.59 - 1.43) 51/53 0.97 (0.61 - 1.53)
TC 134/163 1.0 (reference) 60/68 1.06 (0.68 - 1.64) 50/40 1.37 (0.83 - 2.26)
CC 37/39 1.0 (reference) 6/21 0.24 (0.08 - 0.77) 0.02 0.31 0.25 9/9 0.99 (0.32 - 3.11)
CLOCK
rs3749474
CC 123/131 1.0 (reference) 52/55 0.97 (0.68 - 1.37) 48/42 1.08 (0.73 - 1.59)
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Table 5 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each polymorph-
ism among women with less than two consecutive night shifts for 5 or more years compared to women with three
consecutive night shifts or women with four or more consecutive night shifts for 5 or more years (Continued)
CT 148/152 1.04 (0.74 -
1.47)
56/63 0.87 (0.46 - 1.63) 47/45 1.84 (0.92 - 3.69)
TT 39/66 0.60 (0.37 -
0.97)
16/29 0.24 (0.05 - 1.18) 0.07 0.56 0.29 13/13 3.15 (0.62 - 16.14)
Ptrend
f = 0.24 Ptrend
f = 0.63
CC 123/131 1.0 (reference) 52/55 0.97 (0.68 - 1.37) 48/42 1.08 (0.73 - 1.59)
CT 148/152 1.0 (reference) 56/63 0.64 (0.30 - 1.36) 47/45 1.44 (0.63 - 3.31)
TT 39/66 1.0 (reference) 16/29 0.30 (0.05 - 1.77) 13/13 2.12 (0.30 - 15.15)
CSNK1E
rs1534891
GG 241/258 1.0 (reference) 98/112 0.93 (0.66 - 1.309) 82/76 1.12 80.77 - 1.62)
GA 62/77 0.83 (0.57 -
1.23)
17/35 0.55 (0.30 - 1.01) 0.05 0.21 0.23 25/25 1.09 (0.61 - 1.95)
AA 5/9 0.51 (0.16 -
1.60)
2/1 2.00 (0.17 - 23.92) 1/2 0.39 (0.03 - 4.68)
Ptrend
f = 0.13 Ptrend
f = 0.66
GG 241/258 1.0 (reference) 98/112 0.93 (0.66 - 1.309) 82/76 1.12 80.77 - 1.62)
GA 62/77 1.0 (reference) 17/35 0.63 (0.31 - 1.28) 25/25 1.11 (0.56 - 2.21)
AA 5/9 1.0 (reference) 2/1 2.58 (0.14 - 91.16) 1/2 2.84 (0.08 - 96.47)
rs5757037
CC 126/154 1.0 (reference) 49/57 1.10 (0.68 - 1.76) 41/38 1.28 (0.75 - 2.70)
CT 137/140 1.11 (0.79 -
1.58)
51/77 0.67 (0.45 - 0.99) 0.05 0.13 0.18 49/45 1.14 (0.74 - 1.77)
TT 43/43 1.04 (0.63 -
1.71)
14/16 0.90 (0.43 - 1.90) 16/16 1.00 (0.49 - 2.05)
Ptrend
f = 0.57 Ptrend
f = 0.22
CC 126/154 1.0 (reference) 49/57 1.10 (0.68 - 1.76) 41/38 1.28 (0.75 - 2.70)
CT 137/140 1.0 (reference) 51/77 0.65 (0.42 - 1.02) 49/45 1.08 (0.66 - 1.75)
TT 43/43 1.04 (0.63- 1.71) 14/16 0.89 (0.38 - 2.10) 16/16 0.97 (0.42 - 2.23)
NPAS2
rs2305160
GG 136/134 1.0 (reference) 52/57 0.86 (0.54 - 1.36) 50/42 1.15 (0.70 - 1.88)
GA 130/151 0.84 (0.59 -
1.18)
51/69 0.84 (0.56 - 1.25) 43/41 1.10 (0.70 - 1.74)
AA 41/56 0.72 (0.45 -
1.18)
18/21 0.87 (0.45 - 1.69) 14/13 1.22 (0.56 - 2.64)
Ptrend
f = 0.21 Ptrend
f = 0.79
rs2305160
GG 136/134 1.0 (reference) 52/57 0.86 (0.54 - 1.36) 50/42 1.15 (0.70 - 1.88)
GA 130/151 1.0 (reference) 51/69 0.95 (0.61 - 1.50) 43/41 1.19 (0.72 - 1.96)
AA 41/56 1.0 (reference) 18/21 1.10 (0.50 - 2.40) 14/13 1.43 (0.58 - 3.52)
rs17024926
TT 110/133 1.0 (reference) 60/66 1.22 (0.78 - 1.92) 36/45 1.03 (0.61 - 1.75)
TC 148/178 1.08 (0.76 -
1.52)
55/64 0.98 (0.66 - 1.47) 54/46 1.23 (0.80 - 1.89)
CC 47/38 1.51 (0.90 -
2.52)
6/21 0.33 (0.13 - 0.84)
0.020
0.24 0.23 17/10 1.89 (0.85 - 4.23)
Ptrend
f = 0.28 Ptrend
f = 0.05
TT 110/133 1.0 (reference) 60/66 1.22 (0.78 - 1.92) 36/45 1.03 (0.61 - 1.75)
TC 148/178 1.0 (reference) 55/64 1.01 (0.65 - 1.57) 54/46 1.28 (0.81 - 2.04)
CC 47/38 1.0 (reference) 6/21 0.24 (0.09 - 0.67)
0.006
0.19 0.22 17/10 1.49 (0.56 - 3.95)
PER2
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Table 5 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each polymorph-
ism among women with less than two consecutive night shifts for 5 or more years compared to women with three
consecutive night shifts or women with four or more consecutive night shifts for 5 or more years (Continued)
rs11695472
AA 173/187 1.0 (reference) 68/87 0.87 (0.59 - 1.29) 63/48 1.37 (0.88 - 2.14)
AC 117/143 0.90 (0.65 -
1.25)
38/54 0.74 (0.47 - 1.16) 36/44 0.87 (0.54 - 1.39)
CC 22/21 1.24 (0.64 -
2.39)
16/7 2.69 (1.08 - 6.73) 0.03 0.28 0.25 9/8 1.32 (0.48 - 3.65)
Ptrend
f = 0.93 Ptrend
f = 0.79
AA 173/187 1.0 (reference) 68/87 0.87 (0.59 - 1.29) 63/48 1.37 (0.88 - 2.14)
AC 117/143 1.0 (reference) 38/54 0.83 (0.50 - 1.39) 36/44 0.93 (0.55 - 1.55)
CC 22/21 1.0 (reference) 16/7 1.91 (0.59 - 6.22) 9/8 0.83 (0.22 - 3.14)
PER3
rs1012477
GG 203/237 1.0 (reference) 88/97 1.12 (0.77 - 1.58) 66/73 1.02 (0.69 - 1.51)
GC 95/100 1.10 (0.78 -
1.56)
22/51 0.42 (0.24 - 0.72)
0.002
0.02 0.08 35/24 1.56 (0.91 - 2.68)
CC 9/7 1.69 (0.58 -
4.93)
3/1 3.42 (0.35 - 33.40) 3/2 1.90 (0.31 - 11.58)
Ptrend
f = 0.15 Ptrend
f = 0.08
GG 203/237 1.0 (reference) 88/97 1.12 (0.77 - 1.58) 66/73 1.02 (0.69 - 1.51)
GC 95/100 1.0 (reference) 22/51 0.38 (0.18 - 0.66)
0.001
0.01 0.06 35/24 1.46 (0.79 - 2.72)
CC 9/7 1.0 (reference) 3/1 3.00 (0.12 - 77.00) 3/2 1.30 (0.06 - 28.93)
ROR-b
rs3903529
TT 162/183 1.0 (reference) 64/70 1.09 (0.71 - 1.66) 51/47 1.20 (0.75 - 1.93)
TA 123/131 1.08 (0.77 -
1.51)
41/62 0.75 (0.49 - 1.15) 40/47 0.92 (0.59 - 1.46)
AA 22/27 0.98 (0.53 -
1.82)




f = 0.26 Ptrend
f = 0.21
TT 162/183 1.0 (reference) 64/70 1.09 (0.71 - 1.66) 51/47 1.20 (0.75 - 1.93)
TA 123/131 1.0 (reference) 41/62 0.72 (0.44 - 1.16) 40/47 0.94 (0.57 - 1.55)
AA 22/27 1.0 (reference) 13/18 0.78 (0.30 - 2.05) 14/5 3.07 (0.84 - 11.18)
rs7022435
GG 178/194 1.0 (reference) 72/85 0.97 (0.65 - 1.43) 55/56 1.05 (0.67 - 1.64)
GA 115/128 1.00 (0.72 -
1.40)
44/49 1.02 (0.65 - 1.60) 41/32 1.38 (0.84 - 2.26)
AA 15/19 0.93 (0.45 -
1.90)
3/12 0.25 (0.07 - 0.89) 0.03 0.41 0.27 11/8 1.34 (0.52 - 3.41)
Ptrend
f = 0.25 Ptrend
f = 0.15
GG 178/194 1.0 (reference) 72/85 0.97 (0.65 - 1.43) 55/56 1.05 (0.67 - 1.64)
GA 115/128 1.0 (reference) 44/49 1.03 (0.62 - 1.70) 41/32 1.34 (0.78 - 2.92)
AA 15/19 1.0 (reference) 3/12 0.29 (0.06 - 1.33) 11/8 2.18 (0.55 - 8.61)
rs3750420
CC 136/166 1.0 (reference) 52/66 0.99 (0.63 - 1.55) 41/47 1.02 (0.61 - 1.68)
CT 136/143 1.20 (0.86 -
1.68)
60/58 1.24 (0.83 - 1.86) 48/35 1.60 (1.00 - 2.56) 0.05 0.15 0.20
TT 28/31 1.18 (0.67 -
2.08)
6/18 0.37 (0.14 - 0.96) 0.04 0.31 0.25 17/12 1.52 (0.71 - 3.28)
Ptrend
f = 0.82 Ptrend
f = 0.03
CC 136/166 1.0 (reference) 52/66 0.99 (0.63 - 1.55) 41/47 1.02 (0.61 - 1.68)
CT 136/143 1.0 (reference) 60/58 1.13 (0.72 - 1.77) 48/35 1.47 (0.88 - 2.45)
TT 28/31 1.0 (reference) 6/18 0.33 (0.11 - 1.00) 0.05 0.39 0.27 17/12 1.39 (0.54 - 3.60)
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breast cancer risk (data not shown). If these SNPs, or
others in linkage disequilibrium with them, may represent
susceptibility variants for breast cancer, it is possible they
do so by altering the gene expression of the ROR-b gene.
The ROR proteins are involved in regulation of circadian
rhythms by activating transcription of the core circadian
BMAL1 gene [56].
Two polymorphisms in the CRY2 gene (rs11038689 and
rs1401417) had protective effects in women with four or
more night shifts. The biological functions of these SNPs
are not known. These polymorphisms have been found to
be associated with postmenopausal breast cancer risk,
with significant effect modification by menopausal status
where this association was evident only in women with
ER- and/or PR-negative breast tumors but not ER- and/or
PR-positive tumors [57]. This may indicate that these
polymorphisms may influence breast cancer risk through
estrogen and progesterone signaling pathways. ERs and
PRs are important for reproductive performance in
women. Kovanen et al. [46] showed that women with
BMAL1 rs2278749 TT genotypes had more pregnancies
and miscarriages, whereas NPAS2 rs11673746 T carriers
had fewer miscarriages, indicating a possible role of these
polymorphisms affecting age at first birth and also number
of children, both of which are established risk factors for
breast cancer [58].
In the genes controlling melatonin biosynthesis (AANAT)
or melatonin receptors (MTNR1A and MTNR1B), several
SNPs were associated with increased risk of breast cancer.
In the main effects analysis, the variant genotypes of both
of the AANAT polymorphisms were associated with
increased breast cancer risk. However, the risk associated
with the rs3760138 GG genotype was 40% higher in the
most exposed group with four or more night shifts (1.82 vs
1.42). These two SNPs are located in the regulatory regions
of the AANAT gene which could potentially affect the
expression of the AANAT gene. The AANAT gene product
is an acetyltransferase that regulates melatonin biosynthesis
during night and day periods by pineal gland. Polymorph-
isms in this gene have also been associated with sleep disor-
ders, but there are no data on the association between these
polymorphisms and breast cancer risk. The levels of mela-
tonin may also be affected by variants in the genes that
encode melatonin receptors 1A and 1B. The MTNR1B
Table 5 Odds ratios and 95% confidence intervals comparing odds of breast cancer associated with each polymorph-
ism among women with less than two consecutive night shifts for 5 or more years compared to women with three
consecutive night shifts or women with four or more consecutive night shifts for 5 or more years (Continued)
MTNR1A
rs13113549
TT 113/109 1.0 (reference) 48/54 0.94 (0.57 - 1.53) 35/33 1.09 (0.62 - 1.93)
TC 142/155 0.94 (0.66 -
1.35)
59/60 1.08 (0.72 - 1.61) 52/49 1.08 (0.71 - 1.65)
CC 55/75 0.75 (0.48 -
1.18)
16/34 0.47 (0.25 - 0.91) 0.02 0.15 0.20 22/18 1.24 (0.65 - 2.39)
Ptrend
f = 0.08 Ptrend
f = 0.71
TT 113/109 1.0 (reference) 48/54 0.94 (0.57 - 1.53) 35/33 1.09 (0.62 - 1.93)
TC 142/155 1.0 (reference) 59/60 1.03 (0.66 - 1.61) 52/49 1.09 (0.68 - 1.75)
CC 55/75 1.0 (reference) 16/34 0.57 (0.27 - 0.19) 22/18 1.28 (0.61 - 2.68)
MTNR1B
rs10830963
CC 176/195 1.0 (reference) 63/84 0.83 (0.58 - 1.23) 51/50 1.01 (0.64 - 1.61)
CG 105/123 0.86 (0.61 -
1.21)
46/51 1.06 (0.69 - 1.64) 46/45 1.13 (0.73 - 1.75)
GG 21/21 1.05 (0.55 -
2.02)




f = 0.76 Ptrend
f = 0.10
CC 176/195 1.0 (reference) 63/84 0.83 (0.58 - 1.23) 51/50 1.01 (0.64 - 1.61)
CG 105/123 1.0 (reference) 46/51 1.17 (0.71 - 1.93) 46/45 1.26 (0.76 - 2.08)
GG 21/21 1.0 (reference) 11/7 1.44 (0.43 - 4.86) 9/1 9.45 (0.97 - 91.82)
aNumber of cases and controls that were successfully genotyped. bOR derived from unconditional logistic regression, including an interaction term between the
night shift variable and the SNP genotypes, and adjusted for age at diagnosis (cases) or interview (controls), selection period, alcohol use, hormone replacement
therapy for the past 2 years, number of children and history of breast cancer in first-degree family members (mother or sister). cP interaction was obtained from
the interaction term between the SNP genotypes and the night shift variable using frequency of the common genotype in the 0 to 2 night shift group as
reference. Only significant or near-significant values are shown. dThe false-positive report probability (FPRP) was calculated as described by Wacholder et al. [42].
FPRP < 0.2 was considered noteworthy. eThe Bayesian false discovery probability (BFDP) was calculated as described by Wakefield et al. [41]. BFDP < 0.8 was
considered noteworthy. For more details on FPRP and BFDP, see the Methods section. fPtrend values for Cochran-Armitage trend test were calculated from 2×C
tables using frequency of genotypes in cases and controls from 0 to 2 night shift group as reference.
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rs10830963 was associated with increased risk in the high-
level exposed group of women carrying two variant alleles,
without being noteworthy by FPRP and BFDP. The variant
alleles ofMTNR1A rs113113549 polymorphisms were asso-
ciated with decreased risk of breast cancer in the women
with three consecutive night shifts. Night shift workers
have been shown to have substantially reduced melatonin
levels during night work and daytime sleep, and levels
remain low even when a night shift worker sleeps at night
[22].
Strengths and limitations of the study
Our results indicate that some SNPs of the core circa-
dian or melatonin signaling pathways, in combination
with night work, may affect breast cancer risk. These
findings are consistent with the results of recent studies,
including our previous study of the same nurses, sug-
gesting a higher risk with longer duration of intense
night shift work per week [7,9,10]. The reported associa-
tions are biologically plausible, as the polymorphisms in
the genes investigated could influence gene expression,
protein function and protein-protein interactions, all of
which may affect several known risk factors for breast
cancer. However, this is a medium-sized, exploratory
study highlighting the need for investigation of possible
combinatory effects of genetic polymorphisms and night
shift work in breast cancer. The results should be inter-
preted with caution, and larger studies are needed to
confirm the associations found here.
The study may have a number of limitations. A larger
reference group without any night shift work is needed.
Our decision to use women with maximum of two conse-
cutive night shifts as the reference group was made to
ensure a sufficient number of subjects for each genotype.
Furthermore, the metrics of exposure to night work used
in our study are different from those used in other studies;
therefore, the results may not be comparable. We have
selected a limited number of polymorphisms, and, to
cover all SNPs in the core circadian and melatonin signal-
ing pathways, a much larger study (that is, GWAS) is war-
ranted. The selection of genes and polymorphisms differs
from other studies as well and may have affected the out-
comes. Finally, although we set very low prior probabilities
for multiple testing, it is still possible that some associa-
tions may not be true positive or negative findings.
Conclusion
We have found a number of polymorphisms in a num-
ber of core circadian or melatonin biosynthesis and/or
bioavailability pathway genes that could be associated
with breast cancer risk in shift workers. The associations
seem biologically plausible because many of the poly-
morphisms may alter gene expression, mRNA stability
or protein function. Future studies investigating the
genetic and epigenetic functionality of these SNPs, as
well as epigenetic changes in the shift workers, are war-
ranted to understand exact biological mechanisms.
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